PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Mantle cell lymphoma

Drugs in development · updated 30 October 2026

Mantle cell lymphoma: drugs in development

Rare diseasePrevalence 1-9 / 100 000 according to Orphanet · ORPHA:52416

As of 30 October 2026 there are 170 active clinical trials (recruiting or ongoing, phases I–III) on 108 drugs for mantle cell lymphoma. 51 are experimental, that is not yet approved in the United States.

170Active trials
51Experimental drugs
3Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
OrelabrutinibICP-022III9NCT07784101
RocbrutinibIII3NCT07377578
ICP-248III2NCT07784101
NemtabrutinibI–II4NCT03162536
LisaftoclaxAPG-2575, LisafotoclaxII2NCT07272499
TacabrutidegI–II2NCT05294731
ALETA-001I–II1NCT06045910
AutoleucelII1NCT07077512
AVM0703I–II1NCT04329728
AZD5492I–II1NCT06542250
BEAMII1NCT07199296
CD19-targetedII1NCT04718883
CTX112I–II1NCT05643742
GolcadomideCC-99282I–II1NCT07578077
LacutoclaxI–II1NCT07609862
LinperlisibII1NCT06324994
MGTA 456II1NCT03674411
OdronextamabOrdspono®II1NCT03888105
SintilimabSinitilimab, SindilimabII1NCT07077512
SurovatamigAZD0486I–II1NCT06564038
TT-01488II1NCT07855016
VNX-101I–II1NCT06533579
Zilovertamab vedotinII1NCT05458297
ABBV-101I1NCT05753501
ABBV-291I1NCT06667687
AC676I1NCT05780034
AlisertibI1NCT01695941
APG-3288I1NCT07424833
ARC-02I1NCT07691606
CLIC-2201I1NCT06208735
DocirbrutinibI1NCT05602363
EXS73565I1NCT06980116
HDM2005I1NCT07697339
IKS03I1NCT05365659
JWCAR239I1NCT07024147
KeynatinibI1NCT04807881
LP-168I1NCT04775745
LTZ-301I1NCT07121946
NKX019I1NCT05020678
NX-2127I1NCT04830137

Sorted by most advanced phase and number of active trials. Showing 40 of 51 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
RituximabRuxience, RituxanIII47NCT02972840
AcalabrutinibACP-196, Calquence®III24NCT02972840
ZanubrutinibBGB-3111, Brukinsa®III21NCT06742996
BendamustineBendamustin, BedamustineIII18NCT02972840
IbrutinibPCI 32765, Imbruvica®III17NCT01804686
VenetoclaxVentoclax, Venclexta®III17NCT06496308
PirtobrutinibJaypirca®III12NCT04662255
SonrotoclaxBGB-11417, Beqalzi®III8NCT06742996
Hyaluronidase-fihjHydase®, Amphadase®III2NCT03267433
CyclophosphamideCyclophosphamid, CytoxanI–II29NCT06564038
FludarabineFludara, FLUDARABINI–II21NCT03277729
ObinutuzumabGazyva®, Gazyvaro®I–II19NCT05861050
LenalidomideRevlimid, lenalinomideI–II13NCT05861050
CytarabineAra-C, Cytosine ArabinosideI–II12NCT02797470
GlofitamabColumvi®I–II12NCT05861050

Sorted by most advanced phase and number of active trials. Showing 15 of 57 drugs.

All 108 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D020522 “Lymphoma, Mantle-Cell”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch